References
- PiccioliAPrandoniPVenous thromboembolism as first manifestation of cancerActa Haematol2001106131711549772
- PrandoniPLensingAWBullerHRDeep-vein thrombosis and the incidence of subsequent symptomatic cancerN Engl J Med1992327112811331528208
- KhoranaAAFrancisCWCulakovaEFisherRIKudererNMLymanGHThromboembolism in hospitalized neutropenic cancer patientsJ Clin Oncol20062448449016421425
- KhoranaAAFrancisCWCulakovaELymanGHRisk factors for chemotherapy-associated venous thromboembolism in a prospective observational studyCancer20051042822282916284987
- RicklesFRLevineMNEpidemiology of thrombosis in cancerActa Haematol200110661211549771
- FalangaARicklesFRManagement of thrombohemorrhagic syndromes (THS) in hematologic malignanciesHematology Am Soc Hematol Educ Program200716517118024625
- KhoranaAAKudererNMCulakovaELymanGHFrancisCWDevelopment and validation of a predictive model for chemotherapy-associated thrombosisBlood20081114902490718216292
- FalangaABarbuiTRicklesFRLevineMNGuidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and HaemostasisThromb Haemost1993705405428259561
- FalangaADonatiMBPathogenesis of thrombosis in patients with malignancyInt J Hematol20017313714411372723
- FalangaAIacovielloLEvangelistaVLoss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acidBlood199586107210817620161
- FalangaALevineMNConsonniRThe effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trialThromb Haemost19987923279459316
- SeitzRRappeNKrausMActivation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosisBlood Coagul Fibrinolysis199342492548388741
- WadaHSaseTYamaguchiMHypercoagulant states in malignant lymphomaExp Oncol20052717918516244577
- FalangaAMarchettiMVignoliABalducciDClotting mechanisms and cancer: implications in thrombus formation and tumor progressionClin Adv Hematol Oncol2003167367816258469
- FalangaAPanova-NoevaMRussoLProcoagulant mechanisms in tumour cellsBest Pract Res Clin Haematol200922496019285272
- HuttenBAPrinsMHGentMGinsbergJTijssenJGBullerHRIncidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysisJ Clin Oncol2000183078308310963635
- PrandoniPLensingAWPiccioliARecurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood20021003484348812393647
- KhoranaAACancer and thrombosis: implications of published guidelines for clinical practiceAnn Oncol2009201619163019561038
- HirshJWarkentinTEShaughnessySGHeparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safetyChest200111964S94S11157643
- LeeAYLevineMNBakerRILow-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancerN Engl J Med200334914615312853587
- FareedJHoppensteadtDSchultzCBiochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profileCurr Pharm Des20041098399915078128
- SamamaMMGerotziafasGTComparative pharmacokinetics of LMWHsSemin Thromb Hemost200026Suppl 1313811011804
- ErikssonBISoderbergKWidlundLWandeliBTengbornLRisbergBA comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteersThromb Haemost1995733984017667822
- FrydmanALow-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humansHaemostasis199626Suppl 224388707165
- BaraLSamamaMPharmacokinetics of low molecular weight heparinsActa Chir Scand Suppl198854365722847460
- CollignonFFrydmanACaplainHComparison of the pharmacokinetic profiles of three low molecular mass heparins – dalteparin, enoxaparin and nadroparin – administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)Thromb Haemost1995736306407495071
- MismettiPLaporteSDarmonJYBuchmullerADecoususHMeta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgeryBr J Surg20018891393011442521
- DentaliFDouketisJDGianniMLimWCrowtherMAMeta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patientsAnn Intern Med200714627828817310052
- Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessmentENOXACAN Study GroupBr J Surg199784109911039278651
- BergqvistDAgnelliGCohenATDuration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancerN Engl J Med200234697598011919306
- KhoranaAAStreiffMBFargeDVenous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to actionJ Clin Oncol2009274919492619720907
- KakkarAKHaasSWolfHEnckeAEvaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudyThrombos Haemost200594867871
- BergqvistDBurmarkUSFlordalPALow molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patientsBr J Surg1995824965017613894
- HullRDPineoGFSteinPDExtended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic reviewAnn Intern Med200113585886911712876
- RasmussenMSJorgensenLNWille-JorgensenPProlonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label studyJ Thromb Haemost200642384239016881934
- KakkarVVBalibreaJLMartinez-GonzalezJPrandoniPExtended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized studyJ Thromb Haemost201081223122920456751
- SamamaMMCohenATDarmonJYA comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study GroupN Engl J Med199934179380010477777
- AlikhanRCohenATCombeSPrevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX studyBlood Coagul Fibrinolysis20031434134612945875
- LeizoroviczACohenATTurpieAGOlssonCGVaitkusPTGoldhaberSZRandomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patientsCirculation200411087487915289368
- CohenATTurpieAGLeizoroviczAOlssonCGVaitkusPTGoldhaberSZThromboprophylaxis with dalteparin in medical patients: which patients benefit?Vasc Med20071212312717615800
- CohenATDavidsonBLGallusASEfficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trialBMJ200633232532916439370
- LevineMHirshJGentMDouble-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerLancet19943438868897908358
- RiessHPelzerUDeutschinoffGA prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): results of the CONKO 004 trial [abstract]J Clin Oncol200927 abst LBA4506
- RiessHPelzerUHilbigARationale and design of PROSPECTCONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapyBMC Cancer2008836119055847
- MaraveyasAWatersJRoyRGemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)Eur J Cancer Suppl20097362
- HaasSKKakkarAKKemkes-MatthesBPrevention of Venous Thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer – results of the TOPIC studies [abstract]J Thromb Haemost20053 abst OR059
- PerryJRJulianJALaperriereNJPRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant gliomaJ Thromb Haemost201081959196520598077
- AgnelliGGussoniGBianchiniCNadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind studyLancet Oncol20091094394919726226
- GeertsWHBergqvistDPineoGFPrevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest2008133381S453S18574271
- Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence)Int Angiol20062510116116763532
- StreiffMBThe National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patientsThromb Res2010125Suppl 2S128S13320433992
- MandalaMFalangaAPiccioliAVenous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM)Crit Rev Oncol Hematol20065919420416837209
- FargeDBosquetLKassab-ChahmiD2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working groupCrit Rev Oncol Hematol201073314619801193
- MandalaMFalangaARoilaFVenous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the managementAnn Oncol201021Suppl 5v274v27620555096
- LymanGHKudererNMPrevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology GuidelinesThromb Res2010125Suppl 2S120S12720433991
- LymanGHKhoranaAAFalangaAAmerican Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancerJ Clin Oncol2007255490550517968019
- KearonCKahnSRAgnelliGGoldhaberSRaskobGEComerotaAJAntithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed)Chest2008133454S545S18574272
- Van DongenCJvan den BeltAGPrinsMHLensingAWFixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolismCochrane Database Syst Rev20044CD00110015495007
- AklEAVasireddiSRGunukulaSAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerCochrane Database Syst Rev20116CD006649
- BullerHRDavidsonBLDecoususHSubcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolismNew Engl J Med20033491695170214585937
- BullerHRDavidsonBLDecoususHFondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trialAnn Intern Med200414086787315172900
- Van DoormaalFFRaskobGEDavidsonBLTreatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trialsThromb Haemost200910176276919350123
- MeyerGMarjanovicZValckeJComparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled studyArch Intern Med20021621729173512153376
- DeitcherSRKesslerCMMerliGRigasJRLyonsRMFareedJSecondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day periodClin Appl Thromb Hemost20061238939617000884
- HullRDPineoGFBrantRFLong-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancerAm J Med20061191062107217145251
- Trujillo-SantosJNietoJATiberioGPredicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE RegistryThromb Haemost200810043543918766259
- LeeAYParpiaSJulianJRicklesFRPrinsMLevineMRisk factors for recurrent thrombosis and anticoagulant – related bleeding in cancer patients [abstract]J Thromb Haemost20097 abst 107
- CarrierMLe GalGChoRTierneySRodgerMLeeAYDose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patientsJ Thromb Haemost2009776076519245418
- KakkarAHedgesRWilliamsonRKakkarVPerioperative heparin-therapy inhibits late death from metastatic cancerInt J Oncol1995688588821556616
- LebeauBChastangCBrechotJMSubcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” GroupCancer19947438458004580
- SmorenburgSMHettiarachchiRJVinkRBullerHRThe effects of unfractionated heparin on survival in patients with malignancy – a systematic reviewThromb Haemost1999821600160410613641
- HettiarachchiRJSmorenburgSMGinsbergJLevineMPrinsMHBullerHRDo heparins do more than just treat thrombosis? The influence of heparins on cancer spreadThromb Haemost19998294795210605808
- LeeAYRicklesFRJulianJARandomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolismJ Clin Oncol2005232123212915699480
- FalangaAThe effect of anticoagulant drugs on cancerJ Thromb Haemost200421263126515304028
- KakkarAKLevineMNKadziolaZLow molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)J Clin Oncol2004221944194815143088
- AltinbasMCoskunHSErOA randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancerJ Thromb Haemost200421266127115304029
- KlerkCPSmorenburgSMOttenHMThe effect of low molecular weight heparin on survival in patients with advanced malignancyJ Clin Oncol2005232130213515699479
- SiderasKSchaeferPLOkunoSHLow-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trialMayo Clin Proc20068175876716770976
- KudererNMKhoranaAALymanGHFrancisCWA meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complicationsCancer20071101149116117634948
- Lazo-LangnerAGossGDSpaansJNRodgerMAThe effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trialsJ Thromb Haemost2007572973717408406
- IcliFAkbulutHUtkanGLow molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancerJ Surg Oncol20079550751217192920
- Van DoormaalFFDi NisioMOttenHMRichelDJPrinsMBullerHRRandomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancerJ Clin Oncol2011292071207621502549
- GriffithsGOBurnsSNobleSIMacbethFRCohenDMaughanTSFRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancerBMC Cancer2009935519807917
- NorrbyKLow-molecular-weight heparins and angiogenesisAPMIS20061147910216519745
- MarchettiMVignoliARussoLEndothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparinThromb Res200812163764517692905
- KhoranaAASahniAAltlandODFrancisCWHeparin inhibition of endothelial cell proliferation and organization is dependent on molecular weightArterioscler Thromb Vasc Biol2003232110211512920044
- VignoliAMarchettiMRussoLLMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cellsCancer Invest20112915316121261475
- MousaSAMohamedSInhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitorThromb Haemost20049262763315351861
- KhoranaAAFineRLPancreatic cancer and thromboembolic diseaseLancet Oncol2004565566315522652
- ChewHKWunTHarveyDJZhouHWhiteRHIncidence of venous thromboembolism and the impact on survival in breast cancer patientsJ Clin Oncol200725707617194906
- BarberaLThomasGErythropoiesis stimulating agents, thrombosis and cancerRadiother Oncol20109526927620219259
- AgnelliGGeorgeDJFisherWThe ultra-low molecualr weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy : SAVE ONCO study [abstract]J Clin Oncol201129 abst LBA9014
- FalangaAMarchettiMHeparin in tumor progression and metastatic disseminationSemin Thromb Hemost20073368869418000796
- LecumberriRMassutiBLopez VivancoGFontAGonzalez BillalabeitiaERocha EobotAIAdjuvant bemiparin in small cell lung cancer: results from the ABEL study [abstract]Thromb Res2010125Suppl 2 abst S163